Vytorin Actually Works
The data from the IMPROVEIT trial on cardiovascular outcomes for Vytorin have been released. And the combination met the primary endpoint fewer heart attacks and strokes compared to those already on...
View ArticleAHA IMPROVEIT Proves Ezetimibe Benefit CMECE
MedPage Today Statins are good at reducing cholesterol but a statin plus ezetimibe is even better.
View Article'Food environment' needs changing doctors argue
"A Mediterranean diet may be a better way of tackling obesity than calorie counting leading doctors have said" BBC News reports. In a recently published editorial they also argue the...
View ArticleAutomated Reminders Improve Medication Adherence and Cholesterol Control
PORTLAND Ore. Nov. 17 2014 PRNewswire People who received automated reminders were more likely to refill their blood pressure and cholesterol medications according to a study published today in a...
View ArticleMerck's Zetia cuts heart attack stroke risk in longawaited study
CHICAGO Reuters After years of uncertainty a nearly decadelong study showed that Merck & Co's cholesterol drug Zetia significantly lowered the risk of heart attacks and strokes in highrisk heart...
View ArticleVYTORINÂ ezetimibesimvastatin Significantly Reduced Cardiovascular Events...
Merck NYSEMRK known as MSD outside the United States and Canada today announced that the investigational IMPROVEIT study met its primary and all secondary composite efficacy endpoints. In IMPROVEIT...
View ArticleUPDATE 1Merck's Zetia cuts heart attack stroke risk in longawaited study
CHICAGO Nov 17 Reuters After years of uncertainty a nearly decadelong study showed that Merck & Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in highrisk heart patients...
View ArticleAlnylam Presents New PreClinical Data on RNAi Therapeutic Programs for...
New NonHuman Primate Data on ALNPCSsc Show Clamped Knockdown of PCSK9 up to 92 and LDLC Reductions of up to 77 with MonthlyÂSubcutaneous Dosing Regimen; Phase 1 Study with ALNPCSsc on Track to Start...
View ArticleMedical News Today Controversial cholesterollowering drug 'vindicated' in...
A large study has found that the cholesterollowering ezetimibe taken in combination with a statin is beneficial for patients at high risk for heart disease or stroke.
View ArticleODYSSEY ALTERNATIVE PCSK9 Inhibitor for Statin Intolerance
Many patients in the small trial who had been "statinintolerant" managed to stay on lowdose atorvastatin; for those who can't alirocumab could prove to be a good alternative it...
View ArticleMerck & Cos LDLlowering drug Vytorin meets study endpoints
Pharma giant Merck & Co has announced that the study investigating LDLcholesterollowering drug Vytorin ezetimibesimvastatin which combines simvastatin with the nonstatin Zetia ezetimibe has met its...
View ArticleTherapy PCSK9 inhibitors for treating familial hypercholesterolaemia
Familial hypercholesterolaemia is caused by mutations in genes that code for proteins involved in cholesterol metabolism. Patients heterozygous for mutations in LDLR respond to statin treatment whereas...
View ArticleEuropean Commission Grants Marketing Authorization for Gileads HarvoniÂ...
OnceDaily Single Tablet Regimen Eliminates the Need for Interferon and Ribavirin for Patients with Genotype 1 and 4 Hepatitis C without Cirrhosis or with Compensated Cirrhosis Gilead Sciences Inc....
View ArticleExperimental CholesterolLowering Drug Effective Study Reports
MONDAY Nov. 17 2014 An experimental antibody drug could prove effective at lowering LDL "bad" cholesterol levels for patients who have side effects with cholesterollowering statin medications.That's...
View ArticleH.C. Wainwright remains optimistic longterm about Synthetic Biologics
Synthetic Biologics NYSEMKTSYN had its “buy” rating and a price target of $4.00 reiterated at H.C. Wainwright which said it remains optimistic over the long term citing the...
View ArticleRegeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing...
TARRYTOWN&160;N.Y. and PARIS Nov. 19 2014 PRNewswire &160;Regeneron Pharmaceuticals Inc. NASDAQ REGN and Sanofi today announced new detailed positive results from six Phase 3 ODYSSEY trials...
View ArticleSanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing...
PARIS AND TARRYTOWN N.Y. Nov. 19 2014 PRNewswire &160;Sanofi and Regeneron Pharmaceuticals Inc. NASDAQ REGN today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed...
View ArticleAHA PCSK9 Inhibitor Helps in Statin Intolerance CMECE
MedPage Today But can novel agent alirocumab solve the sideeffect dropout issue
View ArticleEarly statin use may give longterm heart benefits
Research shows that taking a cholesterollowering drug for five years in middle age can lower heart and death risks for decades afterward. The benefits seem to grow over time and may last for life.
View ArticleLipitor Lawsuit News More Than 1400 Diabetes Claims Now Pending in Federal...
The Firm is evaluating Lipitor lawsuits on behalf of patients who developed Type 2 diabetes allegedly due to their use of the statin medication.New York New York PRWEB November 19 2014 Lipitor lawsuit...
View Article